<p>In the latest quarter, 16 analysts provided ratings for Insmed (NASDAQ:INSM), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<p>Analysts have set 12-month price targets for Insmed, revealing an average target of $224.19, a high estimate of $269.00, and a low estimate of $162.00. This current average reflects an increase of 0.99% from the previous average price target of $222.00. </p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="price target chart" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png"/></p>

<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Insmed is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Insmed's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p>Stay up to date on Insmed analyst ratings.</p>
<h2>About Insmed</h2>
<p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<h3>Insmed's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Insmed's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>52.36%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Insmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-259.95%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Insmed's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-33.71%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Insmed's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-15.29%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Insmed's debt-to-equity ratio is below the industry average. With a ratio of <b>0.61</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

SBIO

<p>In the latest quarter, 16 analysts provided mixed ratings for Insmed (NASDAQ:INSM), with an average 12-month price target of $224.19, reflecting a 0.99% increase from the previous target. Analysts frequently update their recommendations based on market conditions, with notable changes in ratings and price targets. Insmed's revenue growth rate is approximately 52.36%, but its net margin and return on equity are below industry averages. The company maintains a healthy debt-to-equity ratio of 0.61, indicating less reliance on debt financing. Analyst ratings offer insights into stock performance and future expectations.</p>

Breaking Down Insmed: 16 Analysts Share Their Views